Ibio is a biotechnology business based in the US. Ibio shares (IBIO) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $2.60 – a decrease of 1.89% over the previous week. Ibio employs 16 staff and has a trailing 12-month revenue of around $225,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.60 |
|---|---|
| 52-week range | $1.02 - $7.50 |
| 50-day moving average | $2.00 |
| 200-day moving average | $1.83 |
| Wall St. target price | $4.30 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-4.03 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.6 from 2024-10-14
| 1 week (2024-10-09) | -8.45% |
|---|---|
| 1 month (2024-09-16) | 35.42% |
| 3 months (2024-07-16) | 20.93% |
| 6 months (2024-04-16) | 33.33% |
| 1 year (2023-10-16) | 642.86% |
|---|---|
| 2 years (2022-10-14) | 17.65% |
| 3 years (2021-10-15) | 188.89% |
| 5 years (2019-10-16) | 526.36% |
| Revenue TTM | $225,000 |
|---|---|
| Gross profit TTM | $2.2 million |
| Return on assets TTM | -29.73% |
| Return on equity TTM | -84.15% |
| Profit margin | 0% |
| Book value | $2.47 |
| Market Capitalization | $22.7 million |
TTM: trailing 12 months
We're not expecting Ibio to pay a dividend over the next 12 months.
Ibio's shares were split on a 1:20 basis on 28 November 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ibio shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Ibio shares which in turn could have impacted Ibio's share price.
Over the last 12 months, Ibio's shares have ranged in value from as little as $1.0214 up to $7.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Ibio's is -3.411. This would suggest that Ibio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Ibio has bucked the trend.
iBio, Inc. , a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.